How to prove the ‘added value’ when the concerned innovation is beneficial without producing ‘health’ in a direct way?
How to indicate if an innovation is worthwhile to pay for in view of the claimed benefit it will bring? The goal of the NMB is to compare two interventions by subtracting the NMB of ‘intervention A’ from the NMB of ‘intervention B’, resulting in the incremental NMB (iNMB).
Always wondered how health economic models work? Good news: this blog is developed to guide you through the basic elements of ‘health state transition models’.
To estimate a launch date, some questions will pop-up. Based on the answers, (in combination with a strong strategy) a realistic estimate of the procedural time will become valid.
All market access colleagues involved in the preparation of economic files will be confronted with the aspect of inflation. There are 2 viewpoints versus ‘today’.
We all know that the pathway between the ‘eureka’ moment and the implementation is long. If needed the regulatory bodies can decide to initiate a ‘fast track procedure’.
A robust budget impact estimation starts with knowledge about the volume of patients. But, how to best estimate the optimal target population?
After years of building expertise with Managed entry agreements, several challenges arose. In this blog we give you our opinion.
Quality of life (QoL) in our field of expertise is expressed in ‘utilities’. When performing health economic assessments, the delta utility between 2 clinical settings is measured. Be vigilant, though: the way the QoL is assessed in your study needs to be analysed carefully. In our blog we address some potential difficulties you may encounter.
Each health economic analysis starts with clinical data. But if your sample does not provide mature data, how can you use this data as reliably as possible?
